E-mail
Àλ縻
ÀÓ¿øÁø
¿¬Çõ
´ë±¹¹ÎȰµ¿
ºÐ°úÇÐȸ
¼Ò½ÄÁö
ÀÇ·á°èµ¿Á¤
ÇÐȸµ¿Á¤
Àλ絿Á¤
ÀÌ´ÞÀÇÀÎÅͺä
È­º¸
Áö³­È£º¸±â
Home > ÇÐȸ¼Ò°³ > ¼Ò½ÄÁö > ÇÐȸ µ¿Á¤
Çѱ¹Æóµ¿¸Æ°íÇ÷¾Ð¿¬±¸È¸ 2014 Á¦5ȸ Æóµ¿¸Æ°íÇ÷¾Ð ½ÉÆ÷Áö¾ö 2014.03.14
ÀÛ¼ºÀÚ    °ü¸®ÀÚ Á¶È¸¼ö    1203

Á¦5ȸ Æóµ¿¸Æ°íÇ÷¾Ð ½ÉÆ÷Áö¾ö (2014)

 

 

¾È³çÇϽʴϱî?

 

À¯³­È÷ ´«ÀÌ ¸¹ÀÌ ³»¸®°í Ãß¿ü´ø °Ü¿ïÀ» µÚ·ÎÇÏ°í µûµíÇÑ º½À» ¸ÂÀÌÇÏ¿´½À´Ï´Ù.

 

Á¦5ȸ Æóµ¿¸Æ°íÇ÷¾Ð ½ÉÆ÷Áö¾öÀ» ȸ¿øµéÀÇ °ü½É°ú ±â´ë ¼Ó¿¡ ´ëÀü¿¡¼­ °³ÃÖÇÏ°Ô µÇ¾ú½À´Ï´Ù. À̹ø¿¡´Â ¡°Pulmonary arterial hypertension in pediatric and neonatal patients"¿Í ¡±Inhaled nitric oxide for newborn infant"¸¦ ÁÖÁ¦·Î ÁغñÇÏ¿´½À´Ï´Ù. ½Å»ý¾ÆÇÐȸ ¼±»ý´Ôµé°ú ÇÔ²² ½Å»ý¾Æ PPHNÀÇ Ä¡·á¿¡ °üÇÏ¿© Áö½ÄÀ» ³ª´©°Ô µÊÀ» ±â»Ú°Ô »ý°¢ÇÕ´Ï´Ù. ¿­½ÉÈ÷ ÁغñÇϽŠ¿¬ÀÚµéÀÇ ¹ßÇ¥¿Í ȸ¿ø ¿©·¯ºÐÀÇ Åä·ÐÀ¸·Î °æÇè°ú Áö½ÄÀ» ³ª´©¸ç ¼Ò¾Æ Æóµ¿¸Æ°íÇ÷¾ÐÀÇ ÃÖ½ÅÁö°ßÀ» °øºÎÇÒ ¼ö ÀÖ´Â À¯ÀÍÇÑ ½Ã°£ÀÌ µÇ±â¸¦ ¹Ù¶ø´Ï´Ù.

 

ºÎµð ¸¹Àº ȸ¿øµé²²¼­ ÇÔ²²ÇÏ¿© Áֽñ⸦ ¹Ù¶ø´Ï´Ù.

 

 

Çѱ¹Æóµ¿¸Æ°íÇ÷¾Ð¿¬±¸È¸ ȸÀå ±è¿ë¿í

 

 

 

 

Topics: Pulmonary Arterial Hypertension (PAH)in Pediatric and Neonatal Patients

Date: 2014³â 3¿ù 21ÀÏ(±Ý) 14:00~18:00

Venu: ´ëÀüÃæÃ»±Ç¿ª ÀÇ·áÀçȰ¼¾ÅÍ 3Ãþ ´ë°­´ç (º»°ü°ú 10ºÐ°Å¸®)

ÁÖ°ü: Çѱ¹Æóµ¿¸Æ°íÇ÷¾Ð¿¬±¸È¸ ÁÖÃÖ: ´ëÇѼҾƽÉÀåÇÐȸ

ÆòÁ¡: 3Á¡

µî·Ïºñ: »çÀü(3¿ù17ÀÏ(¿ù)¸¶°¨) Àü¹®ÀÇ 2¸¸¿ø Àü°øÀÇ 1¸¸¿ø °£È£»ç/±â»ç/Çлý 1¸¸¿ø

´çÀÏ Àü¹®ÀÇ 3¸¸¿ø Àü°øÀÇ 2¸¸¿ø °£È£»ç/±â»ç/Çлý 2¸¸¿ø

µî·Ïó: Ãֻ繫±¹Àå 010-3021-1071, fax 1515-010-3021-1071, samu@pediheart.or.kr

ÀԱݰèÁ ½ÅÇÑÀºÇà 100-027-681065 (¿¹±ÝÁÖ: ´ëÇѼҾƽÉÀåÇÐȸ)

 

 

March 21, 2014 (Friday)

 

14:00-14:25 Registration

14:25-14:30 Opening Remark ±è¿ë¿í (Æóµ¿¸Æ°íÇ÷¾Ð¿¬±¸È¸ ȸÀå)

 

 

14:30~16:00 Pulmonary Arterial Hypertension in Pediatric Patients

ÁÂÀå ±è¿ë¿í (±¤Áֱ⵶º´¿ø) ¹Ú¿µºÀ (Á¶¼±ÀÇ´ë)

14:30~15:00 PAH in children: Diagnostic work-up and challenges ºÎ»êÀÇ´ë ¾ç»êº´¿ø Á¶¹ÎÁ¤

15:00~15:30 Non-congenital heart disease associated PAH °æºÏÀÇ´ë ±è¿©Çâ .

15:30~16:00 Interventional and surgical modalities of treatment in PAH ¿¬¼¼ÀÇ´ë ¹ÚÇѱâ

 

16:00~16:20: coffee break

 

 

16:20~17:50 Inhaled nitric oxide for newborn infants

ÁÂÀå ÃÖº´¹Î (°í·ÁÀÇ´ë) ½É¿ì¼· (ºÎõ¼¼Á¾º´¿ø)

16:20~15:50 Clinical indication of iNO ÇѸ²ÀÇ´ë ¼ºÅÂÁ¤

15:50~17:20 Clinical practice for using iNO °í·ÁÀÇ´ë ÀÌÀºÈñ

17:20~17:50 Clinical outcome and side effect of iNO ¼º±Õ°üÀÇ´ë ¾È¼ÒÀ±

 

17:50-18:00 Closing ening Remark ȸÀå ±è¿ë¿í




Àüü °Ô½Ã¹°À» º¾´Ï´Ù.